Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?

• In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million.
• The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing resources can fund operations through the end of 2027.
• Next, we’ll examine how the Merck technology transfer–driven earnings beat reshapes Codexis’s investment narrative and perceived revenue quality.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Codexis Investment Narrative Recap

To own Codexis, you have to believe ECO Synthesis can evolve from early contracts into a durable, higher quality revenue base, while legacy biocatalysis lumpiness fades in importance. The Merck technology transfer–driven Q4 beat and extended cash runway support that thesis in the near term, but they also highlight how concentrated and episodic revenue still is, keeping the biggest risk squarely on revenue visibility and the timing of future ECO Synthesis wins.

The recent agreement to manufacture 50 grams of siRNA using ECO Synthesis for a cardiovascular program is especially relevant here, because it shows the platform beginning to move beyond tiny research volumes. While modest in absolute dollars, it helps connect the Merck tech transfer spike to a broader pipeline of real-world ECO Synthesis usage that could either smooth out revenue or, if projects stall, reinforce concerns about lumpiness.

Yet investors should also weigh how dependent this emerging ECO Synthesis story still is on partner progress and concentrated agreements...

Read the full narrative on Codexis (it's free!)

Codexis' narrative projects $123.5 million revenue and $17.5 million earnings by 2028.

Uncover how Codexis' forecasts yield a $7.08 fair value, a 340% upside to its current price.

Exploring Other Perspectives

Before this Q4 surprise, the most bullish analysts were already modeling US$149.2 million of revenue and US$21.2 million of earnings by 2028, which is a far more optimistic view than the baseline concerns about lumpy sales and clinical attrition, and the latest Merck fueled beat could either strengthen that optimism or force a rethink of how much of Codexis’s growth is tied to one off deals.

Explore another fair value estimate on Codexis - why the stock might be worth over 4x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Codexis research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Codexis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Codexis' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com